Evolus, Inc. (EOLS) Financial Analysis & Valuation | Quarter Chart
Evolus, Inc. (EOLS)
EOLSPrice: $4.37
Fair Value: 🔒
🔒score
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe gl... more
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and t... more
Description
Shares
| Market Cap | $284.31M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | David Moatazedi |
| IPO Date | 2018-02-08 | CAGR | — |
| Employees | 372 | Website | www.evolus.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
EOLS chart loading...
Fundamentals
Technicals
| Enterprise Value | $414.76M | P/E Ratio | -5.46 |
| Forward P/E | 18.5 | PEG Ratio | — |
| P/S Ratio | 0.07 | P/B Ratio | -0.96 |
| P/CF Ratio | -0.41 | P/FCF Ratio | -0.37 |
| EPS | $-0.8 | EPS Growth 1Y | -1.23% |
| EPS Growth 3Y | -39.39% | EPS Growth 5Y | -83.47% |
| Revenue Growth 1Y | 10.77% | Gross Margin | 0.67% |
| Operating Margin | -0.11% | Profit Margin | -0.18% |
| ROE | 2.68% | ROA | -0.23% |
| ROCE | -0.22% | Current Ratio | 1.9 |
| Quick Ratio | 1.54 | Cash Ratio | 0.71 |
| Debt/Equity | -6.32 | Interest Coverage | -1.59 |
| Altman Z Score | -2.26 | Piotroski Score | 2 |